174 related articles for article (PubMed ID: 35354905)
1. Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1.
García-Domínguez DJ; Hajji N; López-Alemany R; Sánchez-Molina S; Figuerola-Bou E; Morón Civanto FJ; Rello-Varona S; Andrés-León E; Benito A; Keun HC; Mora J; Tirado ÓM; de Álava E; Hontecillas-Prieto L
Oncogene; 2022 Apr; 41(18):2638-2650. PubMed ID: 35354905
[TBL] [Abstract][Full Text] [Related]
2. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
3. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.
Zhou Z; Yu L; Kleinerman ES
Cancer; 2014 Feb; 120(4):579-88. PubMed ID: 24415532
[TBL] [Abstract][Full Text] [Related]
4. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
6. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
7. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
8. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
9. Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.
Souza BK; da Costa Lopez PL; Menegotto PR; Vieira IA; Kersting N; Abujamra AL; Brunetto AT; Brunetto AL; Gregianin L; de Farias CB; Thiele CJ; Roesler R
Mol Neurobiol; 2018 Sep; 55(9):7242-7258. PubMed ID: 29397557
[TBL] [Abstract][Full Text] [Related]
10. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
11. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 facilitates growth of Ewing sarcoma cells.
Bledsoe KL; McGee-Lawrence ME; Camilleri ET; Wang X; Riester SM; van Wijnen AJ; Oliveira AM; Westendorf JJ
J Cell Physiol; 2014 Dec; 229(12):2049-56. PubMed ID: 24812032
[TBL] [Abstract][Full Text] [Related]
13. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
15. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
16. EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model.
González I; Vicent S; de Alava E; Lecanda F
J Mol Med (Berl); 2007 Sep; 85(9):1015-29. PubMed ID: 17453169
[TBL] [Abstract][Full Text] [Related]
17. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
[TBL] [Abstract][Full Text] [Related]
18. The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.
Sengupta A; Rahman M; Mateo-Lozano S; Tirado OM; Notario V
Int J Oncol; 2013 Sep; 43(3):803-12. PubMed ID: 23857410
[TBL] [Abstract][Full Text] [Related]
19. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
20. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
Johnson KM; Taslim C; Saund RS; Lessnick SL
PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]